MDL | - |
---|---|
Molecular Weight | 578.61 |
Molecular Formula | C32H34O10 |
SMILES | OC1=C(C2=C(O)C(C(C=O)=C(O)C(O)=C3C(C)C)=C3C=C2C)C(C)=CC4=C(C(C)C)C(O)=C(O)C(C=O)=C41.O=C(O)C |
Bcl-xL 0.5-0.6 μM (Ki) |
Bcl-2 0.2-0.3 mM (Ki) |
Gossypol, a natural product isolated from cottonseeds and roots that has been studied as an anticancer agent. The racemic form of Gossypol [(±)-Gossypol] is tested in several clinical trials and is well tolerated. The racemic form Gossypol ((±)-Gossypol) binds to Bcl-xL protein with a K i of 0.5 to 0.6 μM. (±)-Gossypol also potently binds to Bcl-2 protein with a K i value of 0.2-0.3 mM. The natural racemic Gossypol has two enantiomers, namely the (-)-Gossypol and (+)-Gossypol enantiomers. The racemic form and each of the enantiomers of Gossypol are tested against UM-SCC-6 and UM-SCC-14A in 6-day MTT assays. (-)-Gossypol exhibits greater growth inhibition relative to (±)-Gossypol than (+)-Gossypol in both cell lines tested (P<0.001). An intermediate growth inhibitory effect is observed with (±)-Gossypol but this effect is only observed at the higher dose of Gossypol (10 μM, P<0.0001) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT01977209 | Third Military Medical University |
Non-small Cell Lung Cancer
|
September 2013 | Phase 3 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 25 mg/mL ( 43.21 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (insoluble)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.7283 mL | 8.6414 mL | 17.2828 mL |
5 mM | 0.3457 mL | 1.7283 mL | 3.4566 mL |
10 mM | 0.1728 mL | 0.8641 mL | 1.7283 mL |